Biotech

Try Jim Cramer's Action Alerts PLUS
CLICK HERE NOW

Eli Lilly's Alimta Shows Promise in Cancer Study

05/16/08 - 01:06 PM EDT

Elizabeth Trotta

Eli Lilly's (LLY - Cramer's Take - Stockpickr) Alimta significantly delays the time it takes for advanced non-small cell lung cancer to progress when given as a maintenance therapy, according to preliminary results of a late-stage study. These results will to be presented in conjunction with the upcoming American Society of Clinical Oncology annual meeting.

The study looks specifically at Lilly's Alimta as a maintenance drug, given to patients three to six weeks after they complete induction chemotherapy. The drug, which competes with Genentech's (DNA - Cramer's Take - Stockpickr) Avastin and Genentech and OSI Pharmaceutical's (OSIP - Cramer's Take - Stockpickr) Tarceva, is already approved as a second-line treatment.

"This is the first study to show that lung cancer patients can benefit from maintenance therapy," said Tudor-Eliade Ciuleanu, associate professor at the Iuliu Hatieganu University of Medicine and Pharmacy in Romania and lead author of the study.

According to the study, progression-free survival (or the time that it takes the tumor to progress) was significantly longer in patients who received Alimta compared to those who received placebo, 4.3 months vs. 2.6 months, respectively.

Overall survival was 13 months for the Alimta group, vs. 10.2 months for the placebo group, but those results weren't statistically significant. However, final data from this trial aren't expected for another six to 12 months.

In a conference call Friday morning, Bear Stearns analyst Mark Schoenebaum noted that he would be surprised if the final data weren't statistically significant, because at this point only half of the patients have died so the study has little powering at this point.

Previous «
1 2

Headlines & Perspectives

Biotech

Go To Section Home


05/16/08
Genentech's Avastin Passes Key Safety Test

The company shared the news late Thursday and said data will now be available a year earlier than expected.


05/13/08
Iomai Surges on $189 Million Buyout

Foreign biotech Intercell will pay $6.60 a share for Iomi.


05/13/08
ImClone 'Eager' for Erbitux Data Release

The biotech stock has fallen ahead of ASCO on doubts about the FLEX study, but management remains bullish.


08/05/08
Three Internet Stocks That Could Double

These forgotten Internet stocks are being accumulated by hedge funds.


08/15/08
The Five Dumbest Things on Wall Street

Raspberries for Apple; You'll be sorry, UBS; Fortress or Fort Knox? Wholly unappetizing Foods; give Liberty AOL or give them...


08/15/08
McCain Fund-Raising Picks Up

The GOP presidential candidate raised $27 million in July.


08/15/08
Cash-Back Cards Aren't Money in the Bank

Some credit and debit cards give you some cash back on purchases. But you need to manage it well to benefit from it.


Your Recent Quotes: Quote Up0 | Quote Down0
Dow S&P 500 NASDAQ
Oil*
Gold
10 Yr
0.00%
%
%
%
Data delayed 20 min
Sign up for our FREE newsletters now. See All

  • Cramer's Daily Booyah!
  • Before the Bell

Premium Stock Ideas
Access Action Alerts Plus to find out Cramer’s latest picks now!